Go back to Newsroom

Rockville-Based CRO Emmes Groups’ OptymEdge launch the first dedicated ophthalmology clinical trial platform at ARVO

Phase 1 Launch of New eSource Technology Marks OptymEdge’s Evolution Into a Full-Service Ophthalmic Research Partner 

Go back to Newsroom

Go back to Newsroom

2025 DIA Global Annual Meeting: Public Sector Sets the Pace for AI in Drug Discovery and Approval

Go back to Newsroom

Go back to Newsroom

2025 DIA Global Annual Meeting: The Truth About AI Adoption Speed in Clinical Research

Go back to Newsroom

Go back to Newsroom

2025 DIA Annual Meeting: Preparing Operational Teams for AI Workflows in Drug Development

Go back to Newsroom

Go back to Newsroom

2025 DIA Annual Meeting: Why AI and Automation Are Set to Become the New Normal in Clinical Research

Go back to Newsroom

Go back to Newsroom

Navigating Funding Freezes and AI Frontiers

Go back to Newsroom

Go back to Newsroom

Emmes CEO on AI in clinical research

Peter Ronco, CEO, Emmes, shares his long-term vision for artificial intelligence in clinical research.

Go back to Newsroom

Go back to Resources

Patient-Caregiver Discrepancy Score: Multisite Evaluation of a Novel Pediatric Outcome Measure

Authors:

Journal:

PMID:

URL:

DOI:

Keywords:

Abstract:

Go back to Resources

Go back to Resources

Evaluation of the safety and immunogenicity of two fractional intradermal regimens of MVA-BN compared to standard dose vaccination

Authors:

Volume:

Journal:

PMID:

URL:

DOI:

Keywords:

Abstract:

Go back to Resources

Go back to Resources

Differences in benefits of office based opioid treatment: Secondary analyses across sub-groups in the PROUD randomized controlled implementation trial

Authors:

Journal:

PMID:

URL:

DOI:

Keywords:

Abstract:

Go back to Resources